Biogen Unveils Phase III Salanersen Program To Bring Longer-Acting SMA Option

Phase Ib Data Update Reinforces Profile

 
• By Alaric DeArment
  
Spinal muscular atrophy
Biogen presented data for salanersen in spinal muscular atrophy. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Neurological

More from Therapy Areas